# US 2009/0269796 A1 · Methods of detecting and treating myocardial ischemia and myocardial infarction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269796 A1
- Document ID: US20090269796A1
- Status: Published application
- Kind: A1
- Application number: 12/277,740
- Filed: 2008-11-25
- Published: 2009-10-29
- Earliest claimed: 2007-12-05
- Assignees: The General Hospital Corporation
- Inventors: Robert Gerszten; Marc S. Sabatine; Michael A. Fifer
- Web page: https://patentgrep.com/patent/US20090269796A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods of detecting and treating myocardial ischemia and myocardial infarction based on the differential expression of metabolic products are described herein.

## Claims

### Claim 1

A method of detecting myocardial ischemia or myocardial infarction in a subject comprising detecting in a biological sample obtained from the subject a change in the amount of at least one member selected from the group consisting of malonic acid, asymmetric dimethyl arginine (ADMA), succinic acid, anthanilic acid, acetyl-CoA, asymmetric dimethyl arginine (ADMA)/symmetric dimethyl arginine (SDMA), and a metabolic product thereof, thereby detecting myocardial ischemia or early myocardial infarction in the subject.

### Claim at position 2

2-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the change comprises an increase in the amount of at least one member of the group consisting of malonic acid, succinic acid, anthanilic acid, acetyl-CoA, asymmetric dimethyl arginine (ADMA)/symmetric dimethyl arginine (SDMA), and a metabolic product thereof.

### Claim at position 4

10-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein myocardial infarction is detected.

### Claim 17 (depends on 16)

The method of claim 16, wherein the myocardial infarction is early myocardial infarction.

### Claim 18 (depends on 1)

The method of claims 1, wherein myocardial ischemia is detected.

### Claim 19 (depends on 1)

The method of claims 1, wherein the biological sample comprises a blood sample or a preparation thereof.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The method of claims 1, wherein the change is detected after administration of a controlled ischemic insult or planned myocardial infarction to the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the controlled ischemic insult comprises exercise testing, and the planned myocardial infarction comprises alcohol septal ablation for hypertrophic cardiomyopathy.

### Claim at position 13

24-95. (canceled)

### Claim 96

A method of detecting myocardial ischemia or myocardial infarction in a subject comprising detecting a decrease in the amount of at least one member of the group consisting of cholic acid, tyrosine, sucrose, trimethylamine-N-oxide, homoserine, threonine, choline, proline, 3-phosphoglyceric acid, and a metabolic product thereof in a biological sample obtained from the subject, thereby detecting myocardial ischemia or early myocardial infarction in the subject.

### Claim 97

A method of detecting myocardial ischemia or myocardial infarction in a subject comprising detecting an increase in the amount of at least one member of the group consisting of Ile/Leu, taurine, aminoisobutyric acid, glyceraldehyde, xanthine, adenosine diphosphate (ADP), acetoacetate, carnitine, lactose, mevalonic acid lactone, 1-methylhistamine, glutamine, glutamic acid, orotic acid, glycerol-3-P, glycerate-2-P, adenosine monophosphate (AMP), malic acid, ascorbic acid, deoxycytidine monophosphate (DCMP), deoxycytidine diphosphate (DCDP), metanephrine, dimethyl glycine, creatine, ribose-5-P/ribulose-5-P, and a metabolic product thereof in a biological sample obtained from the subject, thereby detecting myocardial ischemia or early myocardial infarction in the subject.

### Claim 98

(canceled)

### Claim 99 (depends on 96)

The method of claim 96, wherein myocardial infarction is detected.

### Claim 100

(canceled)

### Claim 101 (depends on 96)

The method of claim 96, wherein myocardial ischemia is detected.

### Claim 102 (depends on 96)

The method of claim 96, wherein the biological sample comprises a blood sample or a preparation thereof.

### Claim 103

(canceled)

### Claim 104

(canceled)

### Claim 105 (depends on 96)

The method of claim 96, wherein the decrease or increase is detected after administration of a controlled ischemic insult or planned myocardial infarction to the subject.

### Claim 106 (depends on 105)

The method of claim 105, wherein the controlled ischemic insult comprises exercise testing, and the planned myocardial infarction comprises alcohol septal ablation for hypertrophic cardiomyopathy.

### Claim at position 25

107-119. (canceled)

### Claim 120 (depends on 97)

The method of claim 97, wherein myocardial infarction is detected.

### Claim 121 (depends on 97)

The method of claim 97, wherein myocardial ischemia is detected.

### Claim 122 (depends on 97)

The method of claim 97, wherein the biological sample comprises a blood sample or a preparation thereof.

### Claim 123 (depends on 97)

The method of claim 97, wherein the decrease or increase is detected after administration of a controlled ischemic insult or planned myocardial infarction to the subject.

### Claim 124 (depends on 123)

The method of claim 123, wherein the controlled ischemic insult comprises exercise testing, and the planned myocardial infarction comprises alcohol septal ablation for hypertrophic cardiomyopathy.
